Ionis Pharmaceuticals, Inc.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $26.96
- 52-Week Range
- $26.55 – $86.74
- Market Cap
- $4.56B
- P/E (TTM)
- —
- EPS (TTM)
- -3.35
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 11.58
- PEG Ratio
- 27.33
- Return on Equity
- -108.05%
- Return on Assets
- -11.88%
- Gross Margin
- 3.00%
- Operating Margin
- -58.84%
- Profit Margin
- -56.93%
- Current Ratio
- 5.42
- Debt/Equity
- 5.52
- Total Debt
- $2.17B
- Free Cash Flow
- $-371.24M
- Revenue Growth
- 54.90%
- Earnings Growth
- —
- Enterprise Value
- $4.79B
Market Snapshot
About
Ionis Pharmaceuticals is a biotechnology company pioneering RNA-targeted therapeutics. The company uses its proprietary antisense technology platform to design medicines that regulate RNA to treat diseases. Ionis has brought multiple drugs to market and has a robust pipeline targeting neurological diseases, cardiovascular conditions, and rare diseases. The company partners with major pharmaceutical firms and receives royalties from approved drugs including Spinraza for spinal muscular atrophy.